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on the occasion of the 30th anniversary of its invention (1981-2011) 
 
1. Introduction 
One of the 20th century's significant achievements is a discovery of azithromycin (1) and its 
development to commercial product for effective treatment of various infective diseases. 
Owing to its exceptional therapeutic and biopharmaceutical properties, it has come to be 
one of the most successful antibiotics worldwide. For the discovery of azithromycin, in 
addition to receiving numerous awards, in the year 2000, PLIVA's scientists Slobodan Djokic 
and Gabrijela Kobrehel together with the representatives from the US-based Pfizer, Gene 
Michael Bright and Arthur E. Girard, (Anonymous, 2000) were granted the honourable titles 
of "Heroes of Chemistry" by the American Chemical Society (ACS), a non-profit association 
of American chemists and chemical engineers, and the largest association of scientists in the 
world. This prestigious award is taken to be also recognition of the achievement of PLIVA's 
entire team working on azithromycin. The success of azithromycin has positioned PLIVA 
among the few pharmaceutical companies in the world that have developed their own 
blockbuster drug, and has entitled Croatia to join a small group of nations that have 
developed a new antibiotic. 
Nowadays, on the occasion of the 30th anniversary of azithromycin’s invention (1981-2011) 
an increasing prevalence of antibiotic-resistant pathogens suggests that we deeply entered 
into a “Post-Antimicrobial Era” (Cohen 1992; Travis 1994; Kirst 1996b). Investment in newer 
anti-infective platforms is essential and urgent in order to achieve a significant progress in 
our understanding of bacterial resistance and new approaches how to control it. 
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Macrolides as polyketide class of natural products have a long history as effective 
therapeutic agents for treating infectious diseases (Schönfeld & Kirst, 2002; G.T. Hansen et 
al., 2002; T. Kaneko et al., 2006). The popularity of this class of antibiotics, inhibiting bacterial 
protein synthesis by interfering with ribosome function, is largely due to their spectrum of 
activity and their relative safety. They are still in the centre of interest of many research 
groups from academic institutions and pharmaceutical companies and much effort is 
directed toward the discovery of new macrolide antibiotics by chemical modification of the 
existing classes of natural derivatives (Sunazuka et al. 2002; Pal 2006). Antibacterial 
macrolides have attracted considerable attention for two main reasons: (a) the emergence of 
atypical and/or new pathogens and extensive clinical application of these antibiotics had 
resulted in an increasing emergence of bacterial resistance, especially among macrolide-
resistant Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus strains, 
and, therefore, the development of alternative antibacterial agents became essential; (b) 
macrolide derivatives, especially 14- and 15-membered classes, have also become interesting 
for treating important chronic diseases, that is, asthma, chronic sinusitis, diffuse 
panbronchiolitis, cystic fibrosis (Čulić, 2001; Labro, 2000; Labro, 2004), bronchiolitis 
obliterans syndrome (BOS) (Vanaudenaerde et al., 2008; Culic et al., 2006), etc. Some 
macrolides proved active in treatment of malaria (Andersen et al., 1994; Kuschner et al., 
1994; Andersen et al., 1995; Ohrt et al., 2002; Sidhu et al., 2007) and cancer (Romano et al., 
2004; Oyelere et al. 2009; Mwakwari et al. 2010; Bao et al., 2010), showed antiparasitic 
activity (Lee et al. 2011) or act as motilides, ie. macrolides with gastrointestinal motor 
stimulating activity (Takanashi et al. 2009). 
Following this trend, the chemists from PLIVA Pharmaceuticals (Zagreb, Croatia) discovered 
in 1980 the famous azithromycin molecule, 1 (Fig. 1), characterized by unique 15-membered 
macrolide ring system, having a basic methylamino group inserted into the erythromycin 
aglycone (Kobrehel & Djokić 1982;. Kobrehel et al., 1982; Kobrehel & Djokić, 1985; Djokić et al. 
1986; Djokić et al. 1987; Djokić et al. 1988). Soon after the publication of PLIVA's Belgian 
azithromycin patent, researchers at Pfizer (Groton, USA) prepared azithromycin 
independently, as the results of their own research program (Bright 1984).  
Azithromycin was, beside clarithromycin, the leader of the second-generation of 
macrolides, the first representative of new series of macrolides termed “azalides”( 
Schönfeld & Mutak 2002; Mutak 2007), and today the golden standard for macrolide 
antibiotics (Spaventi 2002).  
Azithromycin has broad spectrum of activity against all relevant bacteria causing 
respiratory tract infections, including Haemophilus influenzae and Moraxella catarrhalis 
(Mutak, 2007). It also possesses excellent safety and tolerability profiles and is widely 
prescribed for the treatment of upper and lower respiratory tract infections (Kirst, 1996a; 
Girard et al., 1987; Schönwald et al, 1991; Retsema et al., 1986). The greatest advantages of 
azithromycin compared to other macrolide antibiotics are its unusual pharmacokinetics: 
high tissue distribution and metabolic stability. These properties have led in recent years to 
the widespread use of the azalide scaffold for synthesis of new antibacterial active 
compounds with advantageous pharmacokinetics. 
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Fig. 1. Azithromycin (1) and its position subjected to derivatization 
The growing resistance to antibiotics conferred by microorganisms commonly involved in 
respiratory tract infections has become a serious clinical problem (Prieto et al., 2002). The 
widespread use of macrolides has contributed to the increase of resistance within 
Streptoccoccus pyogenes and Streptoccoccus pneumoniae strains and its level varies worldwide, 
with an alarming upper rate of 25% in some European countries (Granizo et al., 2000; 
Szczypa et al., 2000; Nagai 2002 et al.,; Albrich et al., 2004). Gram-positive S. pyogenes and S. 
pneumonia is the most common bacterial strains implicated in acute pharyngitis, skin and 
soft tissue infections and also one of the most problematic respiratory pathogen 
(Cunningham et al., 2000).  
It has been shown that the resistance to macrolide antibiotics in Gram-positive 
microorganisms can be attributed to two main mechanisms: target site modification and active 
efflux (Nakajima et al., 1999). It is known that macrolides exert their activity by binding to the 
large 50S ribosomal subunit. They inhibit bacteria protein synthesis at peptidyl transferase 
center by blocking the nascent peptide exit tunnel (Poehlsgarrd & Douthwaite, 2003). The 
modification of specific rRNA bases can prevent macrolides to bind. This may be due to the 
action of methylases encoded either by erm(B) or erm(A) genes (Weisblum, 1998). The 
methylases are responsible for developing macrolide, lincosamide and streptogramin B (MLSB) 
resistance; inducible-(iMLS) or constitutive (cMLS). The active drug efflux is another common 
type of resistance developed by bacteria and is mediated by the membrane-associated pump 
encoded by the mef(A) gene (Sutcliffe et al. 1996). In order to overcome the resistance problems, 
lots of efforts have been made worldwide to search for novel and more potent agents with all 
of the desirable features of the earlier generation of macrolides.  
The discovery of highly potent representatives of the third-generation of macrolides, like 
ketolides (Agouridas 1998), acylides (Tanikawa et al. 2001; Tanikawa et al. 2003), 
anhydrolides (Elliott et al. 1998), etc., was a step forward to tackle the efflux problems 
(LeMahieu et al. 1974; Pestka & LeMahieu 1974a & 1974b, Pestka et al. 1974; Pestka et al. 
1976; Allen. 1977; Van Bambeke et al. 2008)’ to (Tanikawa et al., 2001; Tanikawa et al., 2003), 
anhydrolides (Elliott et al., 1998), etc., was a step forward to tackle the efflux problems 
(LeMahieu et al., 1974; Pestka & LeMahieu 1974a & 1974b, Pestka et al., 1974; Pestka et al., 
1976; Allen. 1977; Van Bambeke et al., 2008). 
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However, some serious drawbacks have been observed for those compound classes: the 
emergence of resistance developed shortly after their introduction and rare but serious side 
effects which lead to restrictions and withdrawal (Bambeke et al., 2008) as seen recently with 
telithromycin, approved by the United States (USA) Food and Drug Administration (FDA) 
approved in 2004 by for treatment of mild to moderate community-acquired bacterial 
pneumonia (CABP) (Cruzan, 2007; Farrell et al., 2010). 
Recently, considering azithromycin’s beneficial pharmacokinetic properties, our group have 
led the widespread modification of the azalide scaffold (Fig. 1) in a search for new, to 
resistant bacterial strains active azalides (Fajdetić et al., 2010; Fajdetić et al., 2011; Hutinec et 
al., 2010; Kapić et. al, 2010; Kapić et. al, 2011a; Kapić et. al., 2011b; Marušić Ištuk et al., 2011; 
Matanović Škugor et al., 2010; Palej Jakopović et al., 2010; Pavlović et al., 2010; Pavlović & 
Mutak, 2011; Štimac et al., 2010).  
In this paper, we present the short overview leading to the discovery of novel sulfonylureas, 
ureas and thioureas of 15-membered azalides as a new class of compounds and their 
antibacterial activity against some key erythromycin resistant pathogens. Structural features 
that guided design of novel macrolides included (1) a properly attached aryl/heteroaryl-
carbamoyl group for improving activity against MLSB resistance and (2) cleavage of 
cladinose sugar and ketolide backbone for improving potency and activity against efflux 
resistance. It was expected that introduction of unsaturated unit, that is, carbamoyl group, 
on nitrogen at position 9a of 1 (Fig. 1) will significantly change electronic properties and also 
steric environment in the ‘upper part’ of the macrolide. It will also serve as an excellent 
linker for the attachment of various groups affording preparation of a library of compounds 
with the goal of identifying novel bacterial inhibitors. 
2. Novel sulfonylureas, ureas and thioureas of 15-membered azalides 
The first discovered representative of the 15-membered azalides, cyclic amine 2 (Scheme 1) 
named 9-deoxo-9a-aza-9a-homoerythromycin A, permitted a derivatisation line at the 9a-
nitrogen atom (Scheme 1). Its first derivatization was methylation at 9a position and 
synthesis of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, azithromycin (1)(Kobrehel 
& Djokić, 1982).  
Several N-derivatisation lines of azalides skeleton were started in PLIVA in the early 1990s 
(Schönfeld & Mutak 2002; Mutak 2007), and some of the synthesized compounds showed 
antibacterial activity. In that respect, the observed activity of initially prepared 9a-N-
carbamoyl and N-thiocarbamoyl derivatives of 2 (Kujundžić et al., 1995) encouraged us to 
extend our study in this direction. 
Thus, a series of new sulfonylurea, urea and thiourea derivatives of 15-membered azalides 
were prepared in order to study whether antibacterial activity toward resistant strains would 
be achieved by introduction of aryl-sulfonylcarbamoyl/carbamoyl/thicarbamoyl group into 
the azalide molecule and how the activity would be affected by nature and position of the 
substituents in the phenyl ring (Bukvić Krajačić et al., 2005). Of particular interest was to study 
the influence of the linker between sulfonylcarbamoyl/carbamoyl/thicarbamoyl- group and 
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aglycon moiety on the antibacterial activity. A special attention was paid to achieving the 
activity against S. pyogenes and S. pneumonia resistant strains. 
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Scheme 1. Synthesis of sulfonylureas 3, 5 and 7. 
2.1 Sulfonylureas  
Intermediates 2 (Djokić et al., 1986; Djokić et al., 1988) and 4, smoothly reacted with 
substituted benzensulfonyl isocyanates to form 9a-N-[N’-(aryl)sulfonylcarbamoyl] 
derivatives, 3a-3f and 5a-5f in high yields (Scheme 1). The key intermediate, 9a-N-(γ-
aminopropyl) derivative 4 was prepared by standard Michael addition of acrylonitrile to the 
amine 2, followed by catalytic hydrogenation of obtained 9a-N-(β-cyanoethyl) derivative 
with PtO2 as a catalyst (Bright et al., 1988). Derivatives 7a-7f, were prepared by the selective 
cyanoethylation of amine 4 with equivalent amounts of acrylonitrile, followed by the 
addition of the substituted benzensulfonyl isocyanates to the intermediate 6.  
For the sulfonylureas directly linked to macrocyclic ring 3a-3f it was observed that 
compounds with methyl group and chlorine in p- 3b (MIC 1 µg/ml), 3d (MIC 1 µg/ml) and 
o- 3c (MIC 0.5 µg/ml), 3e (MIC 2 µg/ml) positions and fluorine in p-position 3f (MIC 2 
µg/ml) showed significantly improved activity against iMLS resistant S. pyogenes strain 
when compared to azithromycin 1 (MIC 8 µg/ml) and starting amine 2 (MIC 16 µg/ml). 
Also, these compounds exhibited two level of dilution better activity than 2 (MIC 0.25 
µg/ml) and similar activity to 1 (MIC <0,125 µg/ml) against sensitive S. pneumonia (Bukvić 
Krajačić et al. 2005). However, the activities against Gram-negative bacteria were all lower 
than those for 1 and 2. Generally, it was observed that antibacterial activity of the novel 
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arylsulfonylcarbamoyl derivatives 3a-3f, 5a-5f and 7a-7f against all the tested erythromycin 
susceptible (Ery-S) Gram-positive strains decreased in the series 3a-3f > 5a-5f > 7a-7f by the 
introduction of a propyl linker and additional cyanoethyl side chain. 
2.2 Novel ureas and thioureas & macrolide-sulfonamide conjugate 
Various 9a-carbamoyl and thiocarbamoyl derivatives 8 & 9 were prepared (Scheme 2) by 
reaction of intermediate 2 with corresponding isocyanates or isothiocyanates (Kujundžić et 
al., 1995). Reactions were usually conducted in toluene to achieve easily crystallisable N-
alkyl or N-aryl substituted ureas. Structures of the N-isopropyl– (8a) (Kujundžić et al., 1995) 
and N-(4-pyridyl)– (8g) (Sheldrick et al., 1995) derivatives were confirmed by single crystal 
X-ray analysis. In biological testing, only a few derivatives 8 & 9 showed moderate 
antibacterial activity. Additional halogen-aryl derivatives of 8 & 9 have been synthesized 
showing moderate activity against resistant strains (Marušić-Ištuk et al., 2000). 
Introduction of novel interactive groups into the azalide backbone resulted in further 
improvements in activity. Strategy which involved macrolide conjugates incorporating 
antibacterial sulfonamides, such as sulfanilamide, sulfabenz, sulfapyridine and 
sulfamethoxazole, showed an increased affinity for the ribosome (Bukvić Krajačić et al., 
2007). Significant activity against inducible resistant S. pyogenes strains was observed by 
modifications at position 9a of an azalide lacton ring, by the carbamoyl group linked 
sulfonamides (Scheme 3). Conjugates of 15-membered azalides and sulfonamides 10a-10d 
were prepared by the reaction of 2 (Djokić et al. 1986; Djokić et al. 1988) with 4-
(chlorosulfonyl)phenylisocyanate. The smoothly formed 9a-(4-chlorosulfonylpheyl)-
carbamoyl derivative was transformed without the isolation into the compounds 10a-10d, 
by the reaction of ammonia, aniline, 2-aminopyridine and 5-methyl-3-aminoisoxasole, 
respectively.  
Azalide-sulfonamide conjugates 10a and 10b possess two to three times better activity 
against iMLS resistant S. pyogenes strain (MIC 2 µg/ml) when compared to both 
azithromycin 1 (MIC 8 µg/ml) and starting cyclic amine 2 (MIC 16 µg/ml) (Bukvić Krajačić 
et al., 2007). These activities are comparable to those observed for azalide sulfonylureas 3a-
3f (Bukvić Krajačić et al., 2005). New azithromycin-sulfonamide conjugates 10a and 10b 
exhibit somewhat lower activity than 1 against sensitive S. pneumonia and S. pyogenes strains. 
Furthermore, the 10c and 10d showed in general lower activity against most of the tested 
bacterial strains except for sensitive S. aureus and M. catarrhalis where better activity was 
observed in comparison with 10a and 10b analogs (Bukvić Krajačić et al., 2007). 
 Further expanding the range of antimicrobial activity, especially against MLSB and efflux-
mediated resistant S. pyogenes and S. pneumoniae strains was achieved by introduction of 
carbamoyl and thiocarbamoyl groups attached on propyl linker at the  9a position (Bukvić 
Krajačić et al., 2009). Novel N’’-aryl substituted 9a-(N’-carbamoyl/thiocarbamoyl-γ-
aminopropyl)- 11, 12 and 9a-[N’-(β-cyanoethyl)-N’-(carbamoyl/thiocarbamoyl-γ-
aminopropyl)]- 13, 14 derivatives were obtained according to efficient procedure described 
for the preparation of the previous classes of compounds (Scheme 2) (Bukvić Krajačić et al., 
2005 & 2007).  
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Scheme 2. Synthesis of novel ureas and thioureas of 15-membered azalides and azalide-
sulfonamide conjugates 
Ureas 11 and 13 and thioureas 12 and 14 (Bukvić Krajačić et al., 2009) showed a significant 
improvement in antibacterial activity against all tested macrolide-susceptible and resistant 
bacteria in comparison with carbamoyl/thiocarbamoyl derivatives 8 & 9 (Kujundžić et al. 
1995), sulfonylcarbamoyl derivatives 3a-3f (Bukvić Krajačić et al., 2005) and azithromycin-
sulfonamide conjugates 10a-10d (Bukvić Krajačić et al., 2007). Also, these compounds exhibited 
a substantially improved in vitro antimalarial activity against P. falciparum (Bukvić Krajačić et 
al., 2011b; Hutinec et al., 2011). Several ureas bearing naphthyl supstituents (11f, 11g, 11h) 
were superior in vitro to the azithromycin against inducible resistant S. pyogenes (MIC 2 
µg/ml). Ureas 11f, 11g and thioureas 12c, 12d, 12e, 12f possesses good activity against efflux-
mediated resistant S. pyogenes (MIC 4 µg/ml), comparable to azithromycin (MIC 4 µg/ml).  
In general, all tested compounds had high in vitro activity against erythromycin susceptible 
Gram-positive aerobes, S. pneumoniae and S. pyogenes (MIC < 0.125 μg/ml) (Bukvić Krajačić et 
al., 2009). Ureas 11 and 13 and thioureas 12 and 14 exhibited excellent activity against 
susceptible S. aureus (MIC 0.25-1 µg/ml), but lacked activity against resistant S. aureus strains. 
Ureas 11f, 11g and thiourea 12f also showed in vitro activity against efflux-mediated resistant 
S. pneumoniae with MICs 4 μg/ml and their activities were comparable with those observed for 
azithromycin (MIC 8 µg/ml). Ureas 11g, 11h and 13h showed moderate activity against cMLS 
S. pneumonia (MIC 16 µg/ml) (Bukvić Krajačić et al., 2009). In vitro activities of ureas 11 and 13, 
thioureas 12 and 14 against key community-acquired Gram-negative respiratory pathogens 
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were improved in comparison with sulfonylureas 3a-3f (Bukvić Krajačić et al., 2005) and 
azithromycin-sulfonamide conjugates 10a-10d (Bukvić Krajačić et al., 2007). Ureas 11f, 11g and 
11h demonstrated high activity against Moraxella catarrhalis. Naphthyl substituted ureas 11f, 
11g and 11h showed better activity against Gram-negative pathogens involved in respiratory 
tract infections (RTI), M. catarrhalis (MIC 0.25 µg/ml) and H. influenza (MIC 1 µg/ml) than 
derivatives with phenyl ring on the alkyl side-chain 11b-11d. In case of phenylethyl- 
substituents in 11d and 12d the presence of thiocarbamoyl moiety seemed to improve activity 
against H. influenzae. The urea 13 with cyanoethyl chain showed similar antibacterial activity in 
comparison to the urea 11. The observed antibacterial activity of ureas and thioureas increased 
in the series 8 & 9 < 11 & 12 < 13 & 14, by the introduction of a propyl linker and additional 
cyanoethyl side-chain (Bukvić Krajačić et al., 2009). 
On the basis of excellent in vitro antibacterial activity and their structural similarity, several 
compounds 11f, 11g, 11h, 12c, 12d, 12e, 12f, 13h, 14c, 14d, 14e were screened for acid stability, 
cytotoxicity and preliminary pharmacokinetic parametars. In acidic conditions compounds 
exhibited azithromycin like stability (Bukvić Krajačić et al., 2009). In vitro cytotoxicity on Hep 
G2 and THP-1 cell lines measured for the selected set of compounds revealed that all 
compounds showed relatively low cytotoxicity in vitro (IC50s ≥ 4 μM) (Bukvić Krajačić et al., 
2011b). These marked them as potent and selective compounds for further profiling 
(Steinmeyer, 2006). Metabolic stability of ureas and thioureas were screened in vitro using 
human and mouse liver microsomes and only a few were selected for in vivo rat 
pharmacokinetic studies in order to determine their pharmacokinetic profiles (Table 1) (Bukvić 
Krajačić et al., 2011b). All compounds demonstrated good in vitro, metabolic stability with t1/2 
greater than 120 min (t1/2 = 103 min for compound 14d in human liver microsomes). As was 
observed with azithromycin, and in line with the in vitro data, these analogs had a low 
systemic clearance, moderate to high volume of distribution and a very long half-life, however, 
the oral bioavailability was low (12c, 12e) to moderate (Bukvić Krajačić et al., 2011b). 
 
 CL (mL/min/kg) Vd (L/kg) t1/2 (hr) Oral F (%) 
Azithromycin 11.0 20.0 24.0 33.0 
12c 4.0 10.4 30.0 3.4 
12e a 2.3 2.6 13.4 1.3 
14e 24.5 31.7 15.2 21 
CL - blood clearance, Vd – apparent volume of distribution at the terminal phase based on drug 
concentration in blood, t1/2 - half life, a - IV parameters determined in one rat  
Table 1. Pharmacokinetic parameters estimated in blood after intravenous (IV) and oral 
gavage (PO) administration to Sprague-Dawley rats (10 mg/kg IV and 30 mg/kg PO) 
(Bukvić Krajačić t al., 2011b). 
Preliminary in vitro microsomal stability data indicated that these compounds had good 
metabolic stability, as was confirmed by low clearances in vivo for the compounds tested. In 
comparison to azithromycin, known for its extensive tissue distribution, (Schönfeld & 
Mutak, 2002) these derivatives had a tendency toward higher volumes of distribution, in 
line with their increased lipophilic character (approx. 2-3 log units higher than 
azithromycin, according to calculated logP values, data not shown) due to the presence of 
strong lipophilic aromatic phenyl and naphtyl rings in the 9a-N substituent (Bukvić Krajačić 
et al., 2011b). Overall, with increased in vitro activity and promising pharmacokinetic 
properties, this series of molecules represents a good starting platform for the design of 
novel antibacterial and antimalarial azalides. 
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2.3 3-Decladinosyl-derivatives of sulfonylureas, ureas and thioureas  
Introduction of unsaturated, sp2 hybridized, carbamoyl unit at 9a position placed nitrogen 
atom of 2 significantly change electronic properties and also steric environment in the 
‘upper part’ of the macrolide, what resulted in increased antibacterial activity of the novel 
sulfonylureas 3,5,7 (Bukvić Krajačić et al., 2005), azalide-sulfonamide conjugates 10 (Bukvić 
Krajačić et al., 2007), and ureas and thioures 11-14 (Bukvić Krajačić et al., 2009). On the other 
hand, the selectively achieved cleavage of cladinose sugar, significantly changes the 
structural behaviour of the ‘lower part’ of 9a-carbamoyl 15-membered azalides, leading to 
the 3-O-decladinosyl-3-hydroxy ureas and thiouras lacking of any, as expected, antibacterial 
activity (Bukvić Krajačić et al., 2005; Bukvić Krajačić et al., 2007; Marušić Ištuk et al., 2007).  
However, there are some novel highly potent 3-O-decladinosyl derivatives of 14-membered 
macrolides, e.g. ketolides (Agouridas et al, 1998), acylides (Tanikawa et al., 2001; Tanikawa 
et al., 2003), anhydrolides (Elliott et al., 1998), etc. (Schönfeld & Kirst 2002; Pal 2006; Kaneko 
et al. , 2006; Mutak 2007) (Fig. 2), proved active against resistant bacterial strains. 
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Fig. 2. Novel classes of 3-O-decladinosyl derivatives of 14- and 15-membered macrolides 
 
Antimicrobial Agents 94
2.3.1 3-Decladinosyl-3-O-substituted derivatives  
Isopropyl- and 2,4-dichlorophenyl- derivatives of 9a-carbamoyl-6-hydroxy (17 & 18) and 9a-
carbamoyl-6-methoxy azalides (19 & 20) lacking any antibacterial activity, were selected to 
study the effects of the ‘lower part’ of azalide skeleton modifications via chemical 
transformations of hydroxyl group at C-3 position (Scheme 3) (Marušić Ištuk et al., 2007). 
They afforded formation of the new ketolides 23 and 24, anhydrolides 27 and 28, hemiketals 
21 and 22, cyclic ethers 25 and 26, and acylides 29 and 30 (Scheme 4). In order to perform 
chemical transformations on the hydroxyl group at position 3, 2’-hydroxyl group which is 
the most reactive one, was suitably protected. Consequently, reaction of 3-decladinosyl-3-
hydroxy- azalides 17, 18, 19, and 20 with acetic anhydride in the presence of a base smoothly 
afforded 2’-O-acetyl-3-decladinosyl-3-hydroxy-6-hydroxy azalides, that under conditions of 
Pfitzner–Moffat 3-OH group oxidation, followed by subsequent methanolysis of 2’-O-acetyl 
intermediate produces internal 3,6-hemiketal structures 21 and 22. Under the same reaction 
conditions 2’-O-acetyl-3-decladinosyl-3-hydroxy-6-methoxy derivatives afford 3-keto 
azalides 23 and 24 (Scheme 3). Introduction of mesyl group at position C-3 of 6-hydroxy-, 17  
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Scheme 3. Synthesis of 3-decladinosyl-3-O-substituted azalides  
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& 18, and 6-methoxy-, 19 & 20 derivatives and subsequent base-promoted elimination led to 
the formation of different products. Whereas 6-hydroxy derivatives 17 & 18 produce 3,6-
cyclic ethers 25 and 26, 6-methoxy derivatives 19 & 20 afford 2,3-anhydro azalides 27 and 28.  
Among already known 3-acylides of 14-membered macrolides, 3-O-(4-nitrophenyl)acetyl 
derivative of clarithromycin (TEA-0777) showed the best antibacterial activity (Tanikawa et 
al., 2001). Accordingly, 9a-carbamoyl acylides having (4-nitrophenyl)acetyl- functionality 
attached to 3-O position, azalides 29 and 30, were prepared, to test if antibacterial activity 
could be enhanced upon attachment of favorite side-arm.  
3-Decladinosyl-6-hydroxy and 6-methoxy azalides 15 and 16 and 9a-carbamoyl/9a-
thiocarbamoyl derivatives 17, 18, 19 & 20 proved antibacterially inactive against tested 
strains. Similar situation can be seen with 3,6-hemiketals 21 & 22 and 3,6-cyclic ethers 25 & 
26. However, anhydrolides 27 and 28 as well as ketolides 23 and 24 show good antibacterial 
activity against efflux resistant S. pneumonia but lower in comparison to erythromycin. 9a-
Carbamoyl-3-O-(4-nitrophenyl)acetyl- acylides 29 and 30 showed the best antibacterial 
activity against efflux resistant S. pneumoniae (MIC 4 µg/ml), and better in comparison to 
erythromycin (MIC 8 µg/ml). Acylides 29 and 30 also show weak activity against 
erythromycin-resistant S. aureus (Marušić Ištuk et al., 2007). 
2.3.2 3-Decladinosyl-3-hydroxy derivatives   
As expected, 3-decladinosyl-3-hydroxy- azalides 17 – 20 and 31 - 34 (Fig. 3) lacked any 
significant antimicrobial activity (Marušić Ištuk et al., 2007; Bukvić Krajačić et al., 2005; 
Bukvić Krajačić et al., 2007) being consistent with the role cladinose was found to play in 
antimicrobial activity (LeMahieu et.al., 1974; Kaneko et.al., 2006; Pal, 2006; Tanikawa et.al., 
2001; Mutak, 2007).  
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This is supported by recently published NMR binding studies (trNOESY and STD 
experiments) on 6-O-methyl-homoerythromycin derivatives, showing that the absence of 
cladinose sugar has been found to be the main cause of their inability to bind to their target 
ribosome (Novak et al., 2009). Stability study of the most active compounds 11f and 13f in 
the artificial gastric juice (Bukvić Krajačić et al., 2009) led to the formation of two 
decladinosyl derivatives 33a and 34a which were tested only against panel of S. pneumoniae 
strains. As was expected decladinosyl urea derivative 34a did not show activity against 
tested strains. However, decladinosyl urea derivative 33a showed significant activity against 
erythromycin susceptible S. pneumoniae strain (1 µg/ml), as well as efflux-mediated S. 
pneumoniae resistant strain (8 µg/ml) comparable to azithromycin. This finding initiated the 
synthesis of a small library of 3-decladinosyl-3-hydroxy ureas and thioureas of 15-
membered azalides termed “decladinosylides” (Bukvić Krajačić et al., 2011a).  
High reactivity of secondary and primary amino groups of 3-decladinosyl- derivatives 37 
and 38 toward isocyanates and isothiocyanates assured highly site-selective introduction of 
carbamoyl and thiocarbamoyl groups and preparation of ureas 33 & 34 and thioureas 35 & 
36 in high yield (Scheme 4). They were found to posses good antibacterial activities against 
key respiratory Gram-positive and Gram-negative pathogens including efflux-mediated 
resistant strains. 
Among them, most of the synthesized 3-decladinosyl-3-hydroxy derivatives showed 
moderate to high activity against efflux-mediated resistant S. pneumoniae and moderate 
activity against susceptible S. pneumoniae and S. pyogenes strains. Against efflux-mediated 
resistant S. pneumoniae compound 35a (MIC 2 µg/ml) posses better activity compared to 
azithromycin (1) (MIC 8 µg/ml) (Bukvić Krajačić et al., 2011a) and their parent 3-cladinosyl 
analogues 11 & 13 (MIC 4 to 16 µg/ml) ( Bukvić Krajačić et al., 2009), and significantly better 
in comparison to the 3-decladinosyl-3-hydroxy azithromycin (16) (MIC >64 µg/ml).  
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Scheme 4. Synthesis of novel 3-decladinosyl ureas and thioureas of 15-membered azalides. 
The racemic urea derivative 33c showed the highest activity against both, susceptible S. 
pneumoniae and S. pyogenes strains, and the same activity as its 3-cladinosyl analogue (±)-11h 
and azithromycin (MIC <0.125 µg/ml) (Bukvić Krajačić et al., 2009). 
Interestingly, some of discovered 3-decladinosyl-3-hydroxy ureas 33 & 34, and thioureas 35 
& 36, maintain antibacterial activity against Gram-negative pathogens H. influenzae and M. 
catarrhalis (Bukvić Krajačić et al., 2011a) in comparison to their parent 3-cladinosyl 
derivatives 11, 12, 13 & 14, (Bukvić Krajačić et al., 2009) and demonstrate large improvement 
in comparison to the inactive 3-decladinosyl sulfonylureas 31( Bukvić Krajačić et al., 2005) 
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and 3-decladinosyl azithromycin-sulfonamide conjugates 32 (Bukvić Krajačić et al., 2007). 
Activity of (±)-33a and 35a against H. influenzae is only one dilution lower than the 
corresponding MIC of azithromycin (MIC 2 µg/ml). Urea (±)-33c was more potent (MIC  
8 µg/ml) than its 3-cladinosyl analogue (±)-11h (MIC 16 µg/ml) against Enterococcus faecalis 
and 33a showed the same activity against E. coli in comparison to its cladinosyl analogue 
11f. (Bukvić Krajačić et al., 2011a). 
Thus, it seems that appropriate linked urea or thiourea moiety at 9a-N of 3-decladinosyl-3-
hydroxy- azalides might interact with particular ribosome binding sites and “substitute” the 
cladinose sugar interaction. In order to gain more information about that conformational 
analysis of a compound 35a was carried out by using systematic conformational search 
around flexible propyl linker. Analysis of NOE cross peaks in the NOESY spectrum 
indicated that there is no strong interaction between macrolactone ring and the substituent 
at 9a-position of 35a, pointing to the stretched conformations that were also found to be 
most stable ones in the conformational analysis (Bukvić Krajačić et al., 2011a). Superposed x-
ray conformations of ABT-773, (Auerbach et al., 2009), azithromycin (Schlunzen et al., 2003; 
Hansen et al., 2002), two bound conformations of telithromycin from Deinococcus radiodurans 
(Berisio et al. 2003) and Haloarcula marismortui (Hansen et al., 2002) and the lowest 
conformation for compound 35a were shown in Fig. 4 (Bukvić Krajačić et al., 2011a).  
 
Fig. 4. Superposed x-ray conformations for azithromycin (green) (Hansen et al., 2002), ABT-
773 (cyan) ( Auerbach et al., 2009), two conformations of telithromycin from Deinococcus 
radiodurans (magenta)( Berisio et al. 2003) and Haloarcula marismortui (yellow)( Hansen et al., 
2002) complexes and most stable conformation for compound 35a (red) (Bukvić Krajačić et 
al., 2011a). 
It is clear that substituents at different positions have different spatial arrangements with 
respect to macrolactone. Until now there is a number of evidence including here mentioned 
ketolides (Auerbach et al., 2009; Schlunzen et al., 2003; Hansen et al., 2002; Berisio et al., 
2003), that high structural diversity is tolerated within the flexible macrolide-binding site of 
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ribosome. In spite of the knowledge gained so far on macrolide binding, (Novak et al., 2006; 
Novak et al., 2009; Auerbach et al., 2009; Schlunzen et al., 2003; Hansen et al., 2002; Berisio et 
al., 2003) an understanding of the mode of their interactions with ribosome still remain 
incomplete with many issues unresolved. Therefore, it can only be speculated about the 
possible binding mode of the compound 35a but it is likely that the additional interaction 
involving 1-naphthyl-propyl- side-chain, attached at the 9a position, might lead to a further 
stabilization of a complex with ribosome (Bukvić Krajačić et al., 2011a).  
3. Concluding remarks 
In summary, the coupling of a arylsulfonyl and benzenesulfonamido moiety to the 9a 
position of 15-membered azalide scaffold via carbamoyl linker has indicated improvement 
in antibacterial activity of novel azalides.  
 
Fig. 5. Antibacterial activities of urea and thiourea derivatives of 15-membered azalides in 
comparison to sulfonylurea analogues. 
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Hence, newly synthesised sulfonyl ureas of azalides 3b-3f, and azalide-sulfonamide 
conjugates 10a and 10b displayed significantly improved activity against inducible resistant 
S. pyogenes strain when compared to azithromycin.  
In addition, the introduction of carbamoyl and thiocarbamoyl group at the 9a position of 
azithromycin like azalide skeleton via propyl linker proved to be promising method to 
tackle the resistance problems. 
As a result of a preliminary optimization of an alkyl/aryl moiety attached at the carbamoyl 
and thiocarbamoyl group all prepared and tested compounds had high in vitro activity 
against erythromycin susceptible Gram-positive aerobes and Gram-negative 
microorganisms and especially resistant S. pyogenes and S. pneumoniae strains. It was also, 
shown here that urea and thiourea derivatives of 3-decladinosyl-3-hydroxy azalides, 
although lacking a cladinose sugar, showed noticeable antibacterial activity. 
Overall mutual comparison of obtained results can be summarized in three items: 
• The observed increase of antibacterial activity in the series of ureas and thioureas 11, 12, 
13 and 14 (Bukvić Krajačić et al., 2009) in comparison with those of their analogues 8 and 9 
(Kujundžić et al., 1995), was opposite to the results obtained for the sulfonylcarbamoyl 
derivatives 3, 5 and 7 (Bukvić Krajačić et al., 2005) where a decrease of activity was found 
when sulfonylcarbamoyl moiety was further away from the azalide ring (Fig. 6) 
 
Fig. 6. Antibacterial activity of selected novel sulfonylureas, ureas and thioureas of 15-
membered azalides on S. Pneumoniae efflux-mediated (Bukvić Krajačić et al., 2009) and S. 
pyogenes iMLS (Bukvić Krajačić et al., 2005) resistant strains in comparison to azithromycin 
• Several novel sulfonylureas (Bukvić Krajačić et al., 2005), ureas and thioureas (Bukvić 
Krajačić et al. 2009) of 15-membered azalides showed same or  significantly better activity 
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on S. pneumoniae efflux-mediated and S. pyogenes iMLS resistant strains in comparison to 
azithromycin (Fig 7). Among them, new ureas with naphtyl substituents (11f, 11g & 11h) 
showed better activity against inducible resistant S. pyogenes in comparison to 
azithromycin. Ureas 11f & 11g and thioureas 12c, 12d, 12e and 12f possess good activity 
against efflux-mediated resistant S. pyogenes, comparable to azithromycin. 
 
Fig. 7. Antibacterial activity of 3-decladinosyl-3-hydroxy ureas and thioureas on  
S. pneumoniae efflux-mediated resistant strain (Bukvić Krajačić et al., 2011) in comparison to 
their parent 3-cladinosyl analogues (Bukvić Krajačić et al., 2009) and test standards 
azithromycin (1) and 3-decladinosyl azithromycin (16).  
• Contrary to the well known fact (LeMahieu, et.al., 1974; Kaneko et.al., 2006; Pal, 2006; 
Tanikawa, et.al., 2001; Mutak, 2007) and previous results (Bukvić Krajačić et al., 2005, 
Bukvić Krajačić et al., 2007; Marušić Ištuk et al., 2007), that simple removal of cladinose 
sugar from macrolides significantly decreases antibacterial activity, unexpectedly, some 
of the newly discovered 3-decladinosyl-3-hydroxy ureas 33 & 34, and thioureas 35 & 36 
(Bukvić Krajačić et al., 2011) maintain good antibacterial activity against panel of key 
respiratory Gram-positive and Gram-negative pathogens. Against efflux-mediated 
resistant S. pneumoniae strain they posses comparable or better activity (MIC 2 -16 
µg/ml) to their 3-cladinosyl parent analogues 11 & 13 (MIC 4 -16 µg/ml) (Bukvić 
Krajačić et al., 2009) and azithromycin (1) (MIC 8 µg/ml), and significantly better in 
comparison to the inactive 3-decladinosyl azithromycin (16) (MIC >64 µg/ml) (Fig. 7) 
(Bukvić Krajačić et al., 2011). Also, some 3-decladinosyl-3-hydroxy ureas 33 & 34, and 
thioureas 35 & 36, maintain antibacterial activity against Gram-negative pathogens H. 
influenzae and M. catarrhalis in comparison to their parent 3-cladinosyl derivatives 
(Bukvić Krajačić et al., 2009), and comparable to azithromycin, but demonstrate a large 
improvement in comparison with inactive 3-decladinosyl azithromycin 16 (Bukvić 
Krajačić et al., 2011) and other 3-decladinosyl derivatives reported in literature. These 
small library of 3-decladinosyl-3-hydroxy ureas and thioureas of 15-membered azalides 
we termed “decladinosylides.”  
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In general, novel sulfonylureas, ureas and thioureas of 15-membered azalides and their 3-
decladinosyl-3-hydroxy derivatives showed their potential to serve as a good platform for 
further investigation in order to discover new derivatives having an improved overall 
biological profile with a special emphasis on resistant bacterial strains.  
4. Acknowledgements 
The Ministry of Science, Education and Sports of the Republic of Croatia is acknowledged 
for the financial support (Project No. 006-0000000-3216). 
5. References 
Agouridas, C.; Denis, A.; Auger, J.; Benedetti, Y.; Bonnefoy, A.; Bretin, F.; Chantot, J. F.; 
Dussarat, A.; Fromentin, C.; D’Ambrieres, S. G.; Lachaud, S.; Laurin, P.; Martret, O. 
L.; Loyau, V. & Tessot, N. (1998). Synthesis and Antibacterial Activity of Ketolides 
(6-O-Methyl-3-oxoerythromycin Derivatives):  A New Class of Antibacterials 
Highly Potent Against Macrolide-Resistant and -Susceptible Respiratory 
Pathogens. Journal of Medicinal Chemistry, Vol. 41, No. 21, (September 1998) pp. 
4080-4100, ISSN 0022-2623 
Albrich, W. C.; Monnet, D. L. & Harbarth, S. (2004). Antibiotic Selection Pressure and 
Resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerging 
Infectious Diseases, Vol. 10, No. 3, pp. 514-517, ISSN 1080-6059 
Alihodžić, S.; Fajdetić, A.; Kobrehel, G.; Lazarevski, G.; Mutak, S.; Pavlović, D.; Štimac, V.; 
Čipčić, H.; Dominis Kramarić, M.; Eraković, V.; Hasenöhrl, A.; Maršić, N. & 
Schönfeld, W. (2006). Synthesis and Antibacterial Activity of Isomeric 15-
Membered Azalides. Journal of Antibiotics, Vol. 59, No.12, (December 2006), pp. 753-
769, ISSN 0021-8820 
Allen, N., (1977). Macrolide Resistance in Staphylococcus aureus: Inducers of Macrolide 
Resistance. Antimicrobial Agents Chemotherapy,  Vol. 11, (April 1977), pp. 669-674, 
ISSN 1098-6596. 
Andersen, S. L.; Ager, A. L.; McGreevy, P.; Schuster, B. G.; Ellis, W.; Berman, J. (1994). 
Efficacy of azithromycin as a causal prophylactic agent against murine malaria. 
Antimicrobial Agents Chemotheraphy, Vol. 38, (August 1994). pp. 1862-1863, ISSN 
1098-6596  
Andersen, S. L.; Ager, A.; McGreevy, P.; Schuster, B. G.; Wesche, D.; Kuschner, R.; Ohrt, C.; 
Ellis, W.; Rossan, R.; Berman, J. (1995). Activity of azithromycin as a blood 
schizonticide against rodent and human plasmodia in vivo. The American Journal 
Tropical Medicine and Hygiene, (February 1995). Vol. 52, pp. 159-161, ISSN 0002-9637  
Anonymous (2000) Heroes of Chemistry Recipients, American Chemical Society Portal, 
http://portal.acs.org/portal/acs/corg/content?_nfpb=true&_pageLabel=PP_SUP
ERARTICLE&node_id=1464&use_sec=false&sec_url_var=region1&__uuid=91e8ce
27-b8ba-4450-9088-5835121094b4, Sept. 7, 2011). 
Auerbach, T.; Mermershtain, I.; Bashan, A.; Davidovich, C.; Rozenberg, H.; Sherman, D. H.; 
Yonath, A. (2009). Structural basis for the antibacterial activity of the 12-membered-
ring mono-sugar macrolide methymycin  Biotechnologia, Vol.1, (January 2009), pp. 
24-35, ISSN 0860-7796 
 
Antimicrobial Agents 102 
Bao, K.; Qiao, F.; Liang, L.; Li, H.; Zhu, H.; Zhang, W. & Wu, Y. (2010). Synthesis and 
antiproliferative activity of novel erythromycin derivatives. Medicinal Chemistry 
Communications, Vol. 1, No. 4, (August 2010). pp. 294-298, ISSN 2040-2503 
Berisio, R.; Harms, J.; Schluenzen, F.; Zarivach, R.; Hansen, H.A.S.; Fucini, P. & Yonath, A. 
(2003). Structural Insight into the Antibiotic Action of Telithromycin against 
Resistant Mutants. Journal of Bacteriology, Vol. 185, No. 14, (May 2003), pp. 4276-
4279, ISSN 0021-9193 
Bright, G. M. (Pfizer), (1984). Antibacterial N-methyl 11-aza-10-deoxo-10-dihydro-
erythromycin A and pharmaceutically acceptable acid addition salts thereof, 
intermediates therefore, and processes for their preparation. US 4 474 768, Oct. 2, 
1984 (US Prior. Nov. 15, 1982). 
Bright, G. M.; Nagel, A. A.; Bordner, J.; Watrous, K. A. ; Sciavolino, F. C.; English, A. R.; 
Retsema, J. A. ; Anderson, M. R. ; Brennan, L. A.; Borovoy, R. J.; Cimochowski, C. 
R.; Faiella, J. A. ; Girard, A. E.; Girard, D.; Herbert, C.; Manousos, M. & Mason, R. 
(1988). Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-aza-9a-
homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides. 
Journal of Antibiotics, Vol. 41: No. 8, (February 1988), pp. 1029-1047, ISSN 0021-8820 
Bukvić Krajačić, M.; Kujundžić, N.; Dumić, M.; Cindrić, M.; Brajša, K.; Metelko, B. & Novak, 
P. (2005). Synthesis, Characterization and in vitro Antimicrobial Activity of Novel 
Sulfonylureas of 15-Membered Azalides. Journal of Antibiotics, Vol. 58, No.6, (June 
2005), pp. 380–389, ISSN 0021-8820 
Bukvić Krajačić, M.; Novak, P.; Cindrić, M.; Brajša, K.; Dumić, M. & Kujundžić, N. (2007). 
Azithromycin-sulfonamide conjugates as inhibitors of resistant Streptococcus 
pyogenes strains. European Journal of Medicinal Chemistry, Vol. 42 No. 2, (February 
2007), pp. 138-145, ISSN 0223-5234 
Bukvić Krajačić, M.; Novak, P.; Dumić, M.; Cindrić, M.; Čipčić Paljetak, H. & Kujundžić, N. 
(2009). Novel ureas and thioureas of 15-membered azalides with antibacterial 
activity, against key respiratory pathogens. European Journal of Medicinal Chemistry, 
Vol. 44, No. 9, (September 2009), pp. 3459-3470, ISSN 0223-5234 
Bukvić Krajačić, M.; Dumić, M.; Novak, P.; Cindrić, M.; Koštrun, S.; Fajdetić, A.; Alihodžić, 
S.; Brajša, K. & Kujundžić, N. (2011a) Discovery of Novel Ureas and Thioureas of 3-
Decladinosyl-3-hydroxy 15-Membered Azalides Active Against Efflux-mediated 
Resistant Streptococcus Pneumoniae. Bioorganic & Medicinal Chemistry Letters, Vol. 21 
No. 2, (January 2011), pp. 853-856, ISSN 0960-894X 
Bukvić Krajačić, M.; Perić, M.; Smith, K. S.; Ivezić Schönfeld, Z.; Žiher, D.; Fajdetić, A.; 
Kujundžić, N.; Schönfeld, W.; Landek, G. ; Jelić, D.; Ager, A.; Milhous, W. K. ; Ellis, 
W.; Spaventi, R. & Ohrt , C. (2011b). Synthesis, Structure-Activity Relationship and 
Antimalarial Activity of Ureas and Thioureas of 15-membered Azalides. Journal of 
Medicinal Chemistry, Vol. 54, No. 10, (April 2011), pp. 3595-3605, ISSN 0022-2623 
Čulić, O. ; Bosnar, M.; Marjanovic, N.; Erakovic, V.; Jelic, D. & Verbanac, D. (2006). 9A-
Carbamoyl and Thiocarbamoyl azalides with anti-inflammatory activity PCT Int. 
Appl. WO 2006097849 A1 20060921. 
Čulić, O.; Eraković, V. & Parnham, M. (2001). Anti-inflammatory effects of macrolide 
antibiotics, European Journal of Pharmacology, Vol. 429, No. 1-3, (October), pp.209-229 
ISSN: 0014-2999 
 
Antibacterial Activity of Novel Sulfonylureas, Ureas and Thioureas of 15-Membered Azalides 103 
M. L. Cohen, M. L. (1992). Epidemiology of Drug Resistance: Implications for a Post—
Antimicrobial Era, Science, Vol. 257, No. 5073 (August 1992), pp. 1050-1055); ISSN: 
0036-8075  
Cruzan, S. (2007). FDA Announces Label and Indication Changes for the Antibiotic Ketek, 
February 12, 2007 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm1
08842.htm (Sept. 8, 2011) 
Cunningham, M. W. (2000). Pathogenesis of Group A streptococcal infections. Clinical 
Microbiology Review, Vol. 13, pp. 470-511, ISSN 0983-8512 
Djokić, S.; Kobrehel, G.; Lazarevski, G.; Lopotar, N.; Tamburašev, Z.; Kamenar, B.; Nagl, A. 
& Vicković, I. (1986). Erythromycin series. Part 11. Ring expansion of erythromycin 
A oxime by the Beckmann rearrangement. Journal of Chemical Society, Perkin Trans. I 
(January 1986) pp. 1881–1990 ISSN 1472-7781 
Djokić, S. Kobrehel, G. & Lazarevski, G. (1987). Erythromycin series XII. Antibacterial in 
vitro evaluation of 10-dihydro-10-deoxo-11-azaerythromycin A: synthesis and 
structure activity relationship of its acyl derivatives. Journal of Antibiotics, Vol. 40, 
pp. 1006-1015; ISSN 0021-8820 
Djokić, S; Kobrehel, G.; Lopotar, N.; Kamenar, B.; Nagl, A.& Mrvoš, D. (1988). Erythromycin 
series. Part 13. Synthesis and structure elucidation of 10-dihydro-10-deoxo-11-
methyl-11-azaerythromycin A. Journal of Chemical Research (S), pp. 152~153, ibid., 
Miniprint, pp. 1239-1257, ISSN 0308-2342 
Elliott, R. L.; Pireh, D.; Griesgraber, G.; Nilius, A. M.; Ewing, P. J.; Bui, M. H.; Raney, P. M.; 
Flamm, R. K.; Kim, K.; Henry, R.F.; Chu, D. T. W.; Plattner, J. J. & Or, Y. S.(1998) 
Anhydrolide Macrolides. 1. Synthesis and Antibacterial Activity of 2,3-Anhydro-6-
O-methyl 11,12-Carbamate Erythromycin A Analogues. Journal of Medicinal 
Chemistry, Vol. 41, No. 10, (April 1998), pp. 1651-1659, ISSN 0022-2623 
Fajdetić, A.; Čipčić Paljetak, H.; Lazarevski, G.; Hutinec, A.; Alihodžić, S.; Đerek, M.; Štimac, 
V.; Andreotti, D.; Šunjić, V.; Berge, J.M.; Mutak, S.; Dumić, M.; Lociuro, S.; Holmes, 
D.J.; Maršić, N.; Eraković Haber, V. & Spaventi R., (2010). 4″-O-(ω-Quinolylamino-
alkylamino)propionyl derivatives of selected macrolides with the activity against 
the key erythromycin resistant respiratory pathogens, Bioorganic and Medicinal 
Chemistry, Vol. 18, No. 17, ( September 2010), pp. 6559-6568, ISSN: 09680896 
Fajdetić, A.; Vinter, A.; Čipčić Paljetak, H.; Padovan, J.; Palej Jakopović, I.; Kapić, S.; 
Alihodžić, S.; Filić, D.; Modrić, M.; Košutić-Hulita, N.; Antolović, R.; Ivezić 
Schönfeld, Z.; Mutak, S.; Eraković Haber, V. & Spaventi R. Synthesis, activity and 
pharmacokinetics of novel antibacterial 15-membered ring macrolones, European 
Journal of Medicinal Chemistry Vol.46, No. 8, (August 2011), pp. 3388-3397, ISSN: 
0223-5234 
Farrell, D. J.; Castanheira, M.; Sader, H. S. & Jones, R. N. (2010).The in vitro evaluation of 
solithromycin (CEM-101) against pathogens isolated in the United States and 
Europe (2009), Journal of Infection Vol. 61, No. 6 (December 2010), pp. 476-483; ISSN 
0163-4453 
Girard, A. E.; Girard, D.; English, A. R.; Gotz, T. D.; Cimochowski, C. R.; Faiella, J. A.; 
Haskell, S. L. & Retsema, J. A (1987). Pharmacokinetic and in vivo studies with 
azithromycin (CP-62,993), a new macrolide with an extended half life and excellent 
 
Antimicrobial Agents 104 
tissue distribution. Antimicrobial Agents Chemotheraphy, Vol. 31, (December 1986), 
pp. 1948-1954, ISSN 1098-6596  
Granizo, J.J.; Aguilar, L.; Casal, J.; Dal-Ré, R. & Baquero F. (2000). Streptococcus pyogenes 
resistance to erythromycin in relation to macrolide consumption in Spain (1986-
1997). Journal of Antimicrobial Chemotherapy, Vol. 46, pp. 959-964, ISSN 1460-2091 
Hansen, G. T.; Metzler, K. L.; DeCarolis, E. & Blondeau, J.M.; (2002). The macrolides, Expert 
Opin. Investig. Drugs, Vol. 11, No. 2, (Feb. 2002), pp. 189-215, ISSN 1354-3784, eISSN 
1744-7658.  
Hansen, J. L.; Ippolito, J. A.; Ban, N.; Nissen, P.; Moore, P. B.; Steitz, T. A. (2002). The 
Structures of Four Macrolide Antibiotics Bound to the Large Ribosomal Subunit. 
Molecular Cell, Vol. 10, No. 1, (July 2002), pp. 117-128, ISSN 1097-2765 
Hutinec, A.; Djerek, M.; Lazarevski, G.; Šunjić, V.; Čipčić Paljetak, H.; Alihodžić, S. Eraković 
Haber, V.; Dumić, M.; Maršić N. & Mutak S. (2010). Novel 8a-aza-8a-
homoerythromycin-4''-(3-substituted-amino)propionates with broad spectrum 
antibacterial activity, Bioorganic and Medicinal Chemistry Letters Vol. 20, No. 11 (June 
2010), pp. 3244–3249; ISSN: 0960-894X 
Hutinec, A.; Rupčić, R.; Žiher, D.; Smith, K. S.; Milhous, W. ; Ellis, W. ; Ohrt, C. & Ivezić 
Schönfeld, Z. (2011). An automated, polymer-assisted strategy for the preparation 
of urea and thiourea derivatives of 15-membered azalides as potential antimalarial 
chemotherapeutics. Bioorganic and Medicinal Chemistry, Vol. 19, No. 5, (March 2011), 
pp. 1692-1701, ISSN 0968-0896 
Kaneko, T., Dougherty, T.J. & Magee, T.V. (2006). Macrolide Antibiotics, In: Comprehensive 
Medicinal Chemistry II, D. Triggle, J. Taylor, J. Plattner, M. C. Desai (Eds.), Vol. 7 pp. 
519-566, Therapeutic Areas II, Elsevier, ISBN 0-08-044513-6 
Kapić, S.; Čipčić Paljetak, H.; Alihodžić, S.; Antolović, R.; Eraković Haber, V.; Jarvest, R. L.; 
Holmes, D. J.; Broskey, J. P. & Hunt, E. (2010). 6-Alkylquinolone-3-carboxylic acid 
tethered to macrolides synthesis and antimicrobial profile, Bioorganic and Medicinal 
Chemistry, Vol. 18, No. 17, ( September 2010), pp. 6569-6577, ISSN 0968-0896  
Kapić, S.; Fajdetić, A.; Koštrun, S.; Čikoš, A.; Čipčić Paljetak, H.; Antolović, R.; Holmes, D. J. 
& Alihodžić, S., (2011a). Synthesis and Activity of New Macrolones: Conjugates 
Between 6(7)-(2’-Aminoethyl)-amino-1-cyclopropyl-3-carboxylic acid (2’-
hydroxyethyl) amides and 4’’-Propenoyl-azithromycin, Bioorganic and Medicinal 
Chemistry, In Press, Accepted Manuscript, doi: 10.1016/j.bmc.2011.07.011; Accepted 
Date: 8 July 2011; ISSN 0968-0896 
Kapić, S.; Čipčić Paljetak, H.; Palej Jakopović, I.; Fajdetić, A.; Ilijaš, M.; Štimac, V.; Brajša, K.; 
Holmes, D. J. ; Berge, J. & Alihodžić, S. (2011b). Synthesis of macrolones with 
central piperazine ring in the linker and its influence on antibacterial activity 
Bioorganic and Medicinal Chemistry, In Press, Accepted Manuscript, doi: 
10.1016/j.bmc.2011.07.010; Accepted Date: 8 July 2011; ISSN 0968-0896 
Kirst, H. A. (1996a). Expanding the Role of Macrolide Compounds as Terapeutic Agent, In: 
Studies in Medicinal Chemistry Choudhary, M. I. (Ed.), Vol. 1, Harwood Academic 
Publisher, Amsterdam, pp. 1-47, ISBN: 978-0-444-51572-8  
Kirst, H. A. (1996b). Aminoglycoside, Macrolide, Glycopeptide, and Miscellaneous 
Antibacterial antibiotics, in: Wolf M. E. (Ed.), Burger’s Medicinal Chemistry and Drug 
Discovery, Fifth Ed., Vol. 2, Ch. 32, Wiley Interscience, New York, 1996, pp. 463-525; 
ISBN 0-471 57557-7. 
 
Antibacterial Activity of Novel Sulfonylureas, Ureas and Thioureas of 15-Membered Azalides 105 
G. Kobrehel, G. & S. Djokić, S. (PLIVA), (1982). Nouveaux derives de l’erythromycine A, 
procede pour leur preparation et leur utilisation comme substances 
antibacteriennes, BE 892 357, July 1, 1982, (YU Prior. March 6, 1981) 
Kobrehel, G.; Radobolja, G.; Tamburašev, Z.; & Djokić, S. (PLIVA), (1982). 11-Aza-10-deoxo-
10-dihydroerythromycin A and derivatives thereof as well a process for their 
preparation. US 4 328 334 (1982)  
Kobrehel, G. & Djokić, S. (PLIVA) (1985). 11-Methyl-11-aza-4-O-cladinosyl-6-O-
desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-
oxacyclopentadecane-2-one and derivatives thereof. US 4 517 359, (May 14, 1985) 
Kujundžić, N.; Kobrehel, G.; Banić, Z.; Kelnerić, Z. & Kojić-Prodić, B. (1995) Azalides: 
Synthesis and antibacterial activity of novel 9a-N-(N’-substituted carbamoyl and 
thiocarbamoyl) derivatives of 9-deoxo-9a-aza-9a-homoerythromycin A. European 
Journal of Medicinal Chemistry, Vol. 30, (January 1995), pp. 455–462, ISSN 0223-5234 
Kuschner, R. A.; Heppner, D. G.; Andersen, S. L.; Wellde, B. T.; Hall, T.; Schneider, I.; Ballou, 
W. R.; Foulds, G.; Sadoff, J. C. & Schuster, B. (1994). Azithromycin prophylaxis 
against a chloroquine-resistant strain of Plasmodium falciparum. Lancet, Vol. 343, 
No. 8910, pp. 1396-1397, ISSN 0140-6736 
Labro, M.-T. (2000). Interference of Antibacterial Agents with Phagocyte Functions: 
Immunomodulation or "Immuno-Fairy Tales"?. Clinical Microbiology Review, Vol. 13, 
(October 2000), pp. 615 – 650, ISSN: 1098-6618. 
Labro, M.-T. (2004). Macrolide antibiotics: current and future uses, Expert Opinion in 
Pharmacotheraphy. Vol. 5, No. 3 (March 2004), pp. 541–550, ISSN: 1465-6566 
Lee, Y.; Choi, J. Y.; Fu, H.; Harvey, C.; Ravindran, S.; Roush, W. R.; Boothroyd, J. C. & 
Khosla, C. (2011). Chemistry and Biology of Macrolide Antiparasitic Agents, Journal 
of Medicinal Chemistry. Vol. 54, No. 8 (April 2011), pp 2792–2804, ISSN 0022-2623 
LeMahieu, R. A.; Carson, M.; Kierstead, R. W.; Fern, L. M. & Grunberg E. (1974). Glycoside 
cleavage reactions on erythromycin A. Preparation of erythronolide A. Journal of 
Medicinal Chemistry. (September 1974), Vol. 17, No. 9, pp. 953-956, ISSN 0022-2623 
Marušić-Ištuk, Z.; Kujundžić, N.; Kobrehel, G; Mutak, S & Maršić, N. (2000). Halo 
derivatives of 9-deoxo-9a-aza-9a-homoerythromycin A. WO 00/66603, November 9 
2000 
Marušić Ištuk, Z.; Mutak, S.; Kujundžić, N. & Kragol, G. (2007). Novel 9a-carbamoyl- and 9a-
thiocarbamoyl-3-decladinosyl-6-hydroxy and 6-methoxy derivatives of 15-
membered macrolides. Bioorganic and Medicinal Chemistry, (April 2007), Vol. 15, 
4498-4510, ISSN 09680896 
Marušić Ištuk, Z.; Čikoš, A.; Gembarovski, D.; Lazarevski, G.; Djilović, I.; Matković- 
Čalogović, D. & Kragol, G. (2011). Novel 9a,11-bridged azalides: One-pot synthesis 
of N'-substituted 2-imino-1,3-oxazolidines condensed to an azalide aglycone, 
Bioorganic and Medicinal Chemistry Vol. 19, No. 1, (January 2011), pp. 556–566; ISSN 
0968-0896 
Matanović Škugor, M.; Štimac, V.; Palej, I.; Lugarić, D.; Čipčić Paljetak, H.; Filić, D., Modrić, 
M.; Đilović, I.; Gembarovski, D.; Mutak, S.; Eraković Haber, V.; Holmes, D. J.; 
Ivezić-Schönfeld, Z. & Alihodžić, S. (2010). Synthesis and biological activity of 4''-
O-acyl derivatives of 14- and 15-membered macrolides linked to ω-quinolone-
carboxylic unit, Bioorganic & Medicinal Chemistry, Vol. 18, No. 17 (September 2010), 
pp. 6547–6558; ISSN 0968-0896 
 
Antimicrobial Agents 106 
Mutak, S. (2007). Azalides from Azithromycin to New Azalide Derivatives. Journal of 
Antibiotics, Vol. 60, No. 2, (January 2007), pp. 85–122, ISSN 0021-8820 
Mwakwari, S. C.; Guerrant, W.; Patil, V.; Khan, S. I.; Tekwani, B. L.; Gurard-Levin, Z. A.; 
Mrksich, M. & Oyelere, A. K. (2010). Non-Peptide Macrocyclic Histone Deacetylase 
Inhibitors Derived from Tricyclic Ketolide Skeleton, Journal of Medicinal 
Chemistry,Vol. 53, No. 16, (August 2010), pp 6100–6111; ISSN 0022-2623 
Nagai, K.; Appelbaum, P. C.; Davies, T. A.; Kelly, L. M. ; Hoellman, D. B. ; Tambic 
Andrasevic, A.; Drukalska, L.; Hryniewicz, W. ; Jacobs, M. R.; Kolman, J.; 
Miciuleviciene, J.; Pana, M.; Setchanova, L.; Konkoly Thege, M.; Hupkova, H.; 
Trupl, J. & Urbaskova, P. (2002). Susceptibility to Telithromycin in 1,011 
Streptococcus pyogenes Isolates from 10 Central and Eastern European Countries. 
Antimicrobial Agents Chemotheraphy, Vol. 46, No. 2, pp. 546-549, ISSN 1098-6596 
Nakajima, Y. (1999). Mechanisms of bacterial resistance to macrolide antibiotics. Journal 
Infection and Chemotherapy, Vol. 5, pp. 61-74, ISSN 1341-321X 
Novak, P.; Tatić, I.; Tepeš, P.; Koštrun, S. & Barber, J. (2006). Systematic Approach to 
Understanding Macrolide-Ribosome Interactions: NMR and Modeling Studies of 
Oleandomycin and Its Derivatives. Journal of Physical Chemistry A, Vol. 110, No. 2, 
(August 2006), pp. 572-579, ISSN 1089-5639 
Novak, P.; Barber, J.; Čikoš, A.; Arsić, B.; Plavec, J.; Lazarevski, G.; Tepeš, P. & Košutić-
Hulita, N. (2009). Free and bound state structures of 6-O-methyl 
homoerythromycins and epitope mapping of their interactions with ribosomes.  
Bioorganic & Medicinal Chemistry, Vol. 17, No. 16, (August 2009), pp. 5857-5867, 
ISSN 09680896 
Ohrt, C.; Willingmyre, G. D.; Lee, P.; Knirsch, C. & Milhous, W. (2002). Assessment of 
azithromycin in combination with other antimalarial drugs against Plasmodium 
falciparum in vitro. Antimicrobial Agents Chemotheraphy, Vol. 46, (August 2002), pp. 
2518-2524, ISSN 1098-6596 
Oyelere, A. K.; Chen, P. C.; Guerrant, W.; Mwakwari, S. C.; Hood, R.; Zhang Y. & Fan, Y. 
(2009). Non-Peptide Macrocyclic Histone Deacetylase Inhibitors, Journal of Medicinal 
Chemistry,Vol. 52, No. 2, (January 2009), pp 456–468; ISSN 0022-2623 
Pal, S. (2006). A journey across the sequential development of macrolides and ketolides 
related to erythromycin. Tetrahedron, Vol. 62, No. 14, (April 2006), pp. 3171–3200, 
ISSN: 0040-4020 
Palej Jakopović, I.; Kragol, G.; Forrest, A. K.; Frydrych, C. S.V.; Štimac, V.; Kapić, S.; 
Matanović Škugor, M.; Ilijaš, M.; Čipčić Paljetak, H.; Jelić, D.; Holmes, D. J.; Hickey, 
D. M.B.; Verbanac, D.; Eraković Haber, V. & Alihodžić, S. (2010) Synthesis and 
properties of macrolones characterized by two ether bonds in the linker. Bioorganic 
and Medicinal Chemistry, Vol. 18, No. 17, ( September 2010), pp. 6578-6588, ISSN: 
09680896  
Pavlović, D.; Fajdetić, A. & Mutak, S. (2010). Novel hybrids of 15-membered 8a- and 9a-
azahomoerythromycin A ketolides and quinolones as potent antibacterials. 
Bioorganic and Medicinal Chemistry, Vol. 18, No. 24, (December 2010), pp. 8566-8582, 
ISSN: 09680896 
Pavlović D. & Mutak , S. (2011). Discovery of 4''-Ether Linked Azithromycin-Quinolone 
Hybrid Series: Influence of the Central Linker on the Antibacterial Activity, ACS 
Med. Chem. Lett., Vol. 2 , No. 5 (May 2011), pp 331–336; ISSN: 1948-5875 
 
Antibacterial Activity of Novel Sulfonylureas, Ureas and Thioureas of 15-Membered Azalides 107 
Pestka, S. & LeMahieu, R. (1974a). Inhibition of [14C]Chloramphenicol Binding to Escherichia 
coli Ribosomes by Erythromycin Derivatives. Antimicrobial Agents Chemotherapy, 
Vol. 6, (July 1974), pp. 39-45, ISSN 1098-6596 
Pestka, S. & Lemahieu, R. A. (1974b). Effect of Erythromycin Analogues on Binding of 
[14C]Erythromycin to Escherichia coli Ribosomes Antimicrobial Agents Chemotherapy,  
Vol. 6, (October 1974), pp. 479-488, ISSN 1098-6596. 
Pestka, S.; Lemahieu, R. A. & Miller, P. (1974). Correlation of Effects of Erythromycin 
Analogues on Intact Bacteria and on [14C]Erythromycin Binding to Escherichia coli 
Ribosomes. Antimicrobial Agents Chemotherapy  Vol. 6, (October 1974), pp. 489-491, 
ISSN 1098-6596. 
Pestka, S.; Vince, R.; LeMahieu, R.; Weiss, F.; Fern, L.; Unowsky, J. (1976). Induction of 
Erythromycin Resistance in Staphylococcus aureus by Erythromycin Derivatives. 
Antimicrobial Agents Chemotherapy, Vol. 9, (January 1976), pp. 128-130, ISSN 1098-
6596 
Poehlsgarrd, J. & Douthwaite, S. (2003). Macrolide antibiotic interaction and resistance on 
the bacterial ribosome. Current Opinion in Investigational Drugs, Vol. 4, pp. 140-144, 
ISSN 1472-4472 
Prieto, J.; Calvo, A. & Gómez-Lus M. L. (2002). Antimicrobial resistance: a class effect?. 
Journal of Antimicrobial Chemotherapy, Vol. 50 (Suppl. S2), pp. 7-12, ISSN 1460-2091 
Retsema, J.; Girard, A.; Schelkly, W.; Manousos, M.; Anderson, M.; Bright, G.; Borovoy, R.; 
Brenan, L. & Manson R. Spectrum and mode of action of azithromycin (CP-62,993), 
a new 15-membered-ring macrolide with improved potency against Gram-negative 
organisms. Antimicrobial Agents Chemotheraphy, Vol. 31, (December 1986), pp. 1939-
1947, ISSN 1098-6596 
Romano, M. F.; Avellino, R.; Petrella, A.; Bisogni, R.; Romano, S. & Venuta, S. (2004). 
Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances 
the apoptosis of melanoma cells. European Journal of Cancer, (December 2004) Vol. 
40, No. 16, pp. 28292836, ISSN 0959-8049 
Schlunzen, F.; Harms, J. M.; Franceschi, F.; Hansen, H. A.; Bartels, H.; Zarivach, R. & Yonath, 
A. (2003) Structural Basis for the Antibiotic Activity of Ketolides and Azalides. 
Structure, Vol. 11, No. 3, pp. 329-338, ISSN 0969-2126 
Schönfeld W. & Kirst H. A. (Eds.), (2002). Macrolide Antibiotics, Birkhäuser Verlag, Basel, 
ISBN: 978-0-12-526451-8  
Schönfeld, W. & Mutak S., (2002). Azithromycin and Novel Azalides In: Macrolide 
Antibiotics, Schönfeld, W.; Kirst H. A. (Eds.), pp. 73-95, Birkhäuser Verlag, Basel, 
ISBN: 978-0-12-526451-8,  
Schönwald, S.; Škerk, V.; Petričević, I.; Cart, V.; Majerus-Mišić, L. & Gunjača, M. (1991). 
Comparison of three-day and five-day courses of azithromycin in the treatment of 
atypical pneumonia. Europen Journal of Clinical Microbiology and Infectious Diseases, 
Vol. 10, pp. 877-880, ISSN 0934-9723  
Sheldrick, G.M.; Kojić-Prodić; B., Banić; Z., Kobrehel; G. & Kujundžić, N. (1995). Structure of 
9-deoxo-9a-N-(N’-(4’-pyridyl)carbamoyl)-9a-aza-9a-homoerythromycin A and 
conformational analysis of analogous 9a-aza 15-membered azalides in solid state. 
Acta Crystallographica B51, Part. 3, (June 1995), pp. 358–366, eISSN 1600-5740 
Sidhu, A. B.; Sun, Q.; Nkrumah, L. J.; Dunne, M. W.; Sacchettini, J. C. & Fidock, D. A. (2007). 
In vitro efficacy, resistance selection, and structural modeling studies implicate the 
 
Antimicrobial Agents 108 
malarial parasite apicoplast as the target of azithromycin. Journal Biological 
Chemistry, Vol. 282, (November 2006), pp. 2494-2504, ISSN 0021-9258  
Spaventi, R. (2002). R&D Challenges for the Future, PLIVA R & D booklet, PLIVA Zagreb 
2002  (http://www.pliva.com/press/news/article/665/RD-Challenges-for-
the-Future.html; Sept. 6, 2011) 
Steinmeyer, A. (2006). The hit-to-lead process at Schering AG: strategic aspects. 
ChemMedChem., Vol. 1, pp. 31-36, ISSN 1860-7187 
Štimac, V.; Matanović Škugor, M.; Palej Jakopović, I.; Vinter, A.; Ilijaš, M.; Alihodžić S. & 
Mutak S. (2010)., Initial Scale-Up and Process Improvements for the Preparation of 
a Lead Antibacterial Macrolone Compound, Organic Process Resesearch and 
Development, Vol. 14, No. 6, (November 2010), pp 1393–1401 ISSN: 1083-6160 
Sunazuka, T.; Omura, S.,.; Iwasaki, S.; Ōmura, S. (2002). Chemical Modification of 
Macrolides, In Macrolide  Antibiotics, Chemistry, Biology and Practice, 2nd. Ed., 
Ōmura S., (Ed.), Academic Press, New York, pp. 99- 180; ISBN 978-0-12-526451-8 
Sutcliffe, J.; Tait-Kamradt, A. & Wondrack, L. (1996). Streptococcus pneumoniae and 
Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a 
common resistance pattern mediated by an efflux system. Antimicrobial Agents 
Chemotheraphy, Vol. 40, pp. 1817-24, ISSN 1098-6596 
Szczypa, K.; Sadowy, E.; Izdebski, R. & Hryniewicz, W. (2004). A rapid increase in macrolide 
resistance in Streptococcus pyogenes isolated in Poland during 1996-2002. Journal of 
Antimicrobial Chemotherapy, Vol. 54, pp. 828~831, ISSN 1460-2091 
Takanashi, H. & Cynshi, O. (2009). Motilides: A long and winding road: Lessons from 
mitemcinal (GM-611) on diabetic gastroparesis, Regulatory Peptides,Vol. 155, No. 1-
3, (June 2009), pp, 18-23; ISSN: 0167-0115 
Tanikawa, T.; Asaka, T.; Kashimura, M.; Misawa, Y.; Suzuki, K.; Sato, M.; Kameo, K.; 
Morimoto, S. & Nishida, A. (2001). Synthesis and Antibacterial Activity of Acylides 
(3-O-Acyl-erythromycin Derivatives):  A Novel Class of Macrolide Antibiotics. 
Journal of Medicinal Chemistry, (October 2001), Vol. 44, No. 24, pp. 4027-4030, ISSN 
0022-2623. 
Tanikawa, T.; Asaka, T.; Kashimura, M.; Suzuki, K.; Sugiyama, H.; Sato, M.; Kameo, K.; 
Morimoto, S. & Nishida, A. (2003). Synthesis and Antibacterial Activity of a Novel 
Series of Acylides:  3-O-(3-Pyridyl)acetylerythromycin A Derivatives. Journal of 
Medicinal Chemistry, Vol. 46, No. 13 (May 2003), pp. 2706-2715, ISSN 0022-2623 
Travis, J. (1994). Reviving the Antibiotic Miracle? Science, Vol. 264, No. 5157 (April 1994), pp. 
360-362; ISSN: 0036-8075  
Vanaudenaerde, B. M.; Meyts, I.; Vos, R.; Geudens, N. ; De Wever, W.; Verbeken, E.K. ; 
VanRaemdonck, D.E.; Dupont, L.J. & Verleden, G.M. (2008). A dichotomy in 
bronchiolitis obliterans syndrome after lung transplantation revealed by 
azithromycin therapy. Eururopean Respiratory Journal, Vol. 32, No. 4, (October 2008), 
pp 832–843, ISSN: 0903-1936 
Van Bambeke, F.; Harms, J. M.; Van Laethem, Y.; Tulkens, P. M. (2008). Ketolides: 
pharmacological profile and rational positioning in the treatment of respiratory 
tract infections.  Expert Opinion in Pharmacotherapy Vol. 9, No. 2, (January 2008), pp. 
267-283, ISSN 1465-6566 
Weisblum, B. (1998). Macrolide resistance. Drug Resistance Updates, Vol. 1, pp. 29-41, ISSN 
1368-7646 
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
